Clinical trial
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
NCT00212290 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00212290 |
|---|---|
| Title | Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Insulin Resistance, Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | pioglitazone, nateglinide, placebo |
| Enrollment | 140 |
| Start date | Nov 1, 2002 |
| Completion | Dec 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Feb 15, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: